Biocartesian
Cambridge, USA· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developer of sensitive liquid biopsy assays for cancer detection and monitoring.
Oncology
Technology Platform
A high-sensitivity NGS and bioinformatics platform for detecting and analyzing ctDNA and other biomarkers in liquid biopsies.
Opportunities
Growing clinical adoption of liquid biopsy for monitoring creates a large, recurring revenue opportunity.
Risk Factors
Failure to achieve widespread insurance coverage would severely limit test adoption and commercial success.
Competitive Landscape
Operates in the crowded, capital-intensive liquid biopsy market dominated by a few large players.